Physician profile
Mark A Vice
NPI 1134188063
$1,866.59
in general payments reported to CMS, 2019-2025
20 companies · $323 in 2025
The $323 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $362 · 2020: $167 · 2021: $270 · 2022: $311 · 2023: $215 · 2024: $220 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $757.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $502.88 | 2019-2025 | |
| Abbott Laboratories | $330.07 | 2022-2025 | Freestyle Libre 3 |
| Amgen INC. | $314.17 | 2019-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $269.13 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Novartis Pharmaceuticals Corporation | $121.20 | 2019-2023 | |
| Exact Sciences Corporation | $47.12 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $31.28 | 2019-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $31.26 | 2020 | |
| Glaxosmithkline, LLC. | $26.69 | 2020-2023 | Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $25.79 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.65 | 2020 | |
| Sanofi-Aventis U.S. LLC | $21.80 | 2025 | |
| Allergan, INC. | $19.49 | 2020 | |
| Antares Pharma, INC. | $16.98 | 2021 | |
| Esperion Therapeutics, INC. | $16.12 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $14.60 | 2024 | Mounjaro |
| Teva Pharmaceuticals USA, INC. | $13.90 | 2019 | |
| Amarin Pharma, INC. | $13.67 | 2019 | |
| Genentech USA, INC. | $13.65 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $13.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Vice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.